Tizanidine

CHEMBL1079 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
253.7 g/mol
LogP
1.1
Phase
4

This muscle relaxant is used to manage muscle spasticity — the tightening or stiffening of muscles — caused by conditions such as multiple sclerosis or spinal cord injury. It works by blocking nerve signals in the brain and spinal cord that trigger muscle contractions. It can cause significant drowsiness and a drop in blood pressure, especially when first starting treatment.

Molekularmasse

253,7100 g/mol

LogP

1,10

TPSA

90,40 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Clc1ccc2nsnc2c1NC1=NCCN1

InChI

InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)

Molecular Formula

C9H8ClN5S

HBD / HBA

2 / 4

Rotierbare Bindungen

2

Schwere Atome

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This muscle relaxant is used to manage muscle spasticity — the tightening or stiffening of muscles — caused by conditions such as multiple sclerosis or spinal cord injury. It works by blocking nerve signals in the brain and spinal cord that trigger muscle contractions. It can cause significant drowsiness and a drop in blood pressure, especially when first starting treatment.

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Yes, Tizanidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1079. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5487. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.